SEARCH:   Advanced

Blood, 10 September 2009, Vol. 114, No. 11, pp. 2232-2235. Prepublished online as a Blood First Edition Paper on June 16, 2009; DOI 10.1182/blood-2009-02-204693. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2009-02-204693v1 114/11/2232    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Google Scholar Articles by Verma, D. Articles by Cortes, J. PubMed PubMed Citation Articles by Verma, D. Articles by Cortes, J. Related Collections Free Research Articles Myeloid Neoplasia Brief Reports Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Brief report Chronic myeloid leukemia (CML) with P190BCR-ABL: analysis of characteristics, outcomes, and prognostic significance Dushyant Verma1, Hagop M. Kantarjian1, Dan Jones2, Rajyalakshmi Luthra2, Gautam Borthakur1, Srdan Verstovsek1, Mary Beth Rios1, and Jorge Cortes1 Departments of 1 Leukemia and 2 Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston The most common BCR-ABL transcripts in chronic myeloid leukemia (CML) are e13a2(b2a2) and e14a2(b3a2). Other transcripts such as e1a2 are rare and their outcome with tyrosine kinase inhibitors (TKI) therapy is undefined. We analyzed 1292 CML patients and identified 14 with only e1a2 transcripts, 9 in chronic phase (CP), 1 in accelerated phase (AP), and 4 in blast phase (BP). Of the CP, 4 achieved complete hematologic response (CHR); 2, complete cytogenetic response (CCyR); 2, partial cytogenetic response (PCyR), and 1 did not respond to imatinib. Five patients progressed to myeloid BP (3), lymphoid BP (1), or AP (1). The AP patient received various TKIs sequentially and achieved only CHR. BP patients received hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, adriamycin, dexamethasone) plus imatinib/dasatinib or idarubicin plus cytarabine (Ara-C); 2 did not respond, 1 had CCyR, and 1 short-lasting complete molecular response (CMR). Overall, cytogenetic responses lasted 3 to 18 months; only 2 achieved major molecular response (MMR) on TKI. P190BCR-ABL CML is rare and is associated with an inferior outcome to therapy with TKI. These patients need to be identified as high-risk patients. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Chronic myeloid leukemia with p190BCR-ABL: prevalence, morphology, tyrosine kinase inhibitor response, and kinase domain mutation analysis Animesh Pardanani, Ayalew Tefferi, Mark R. Litzow, Clive Zent, William J. Hogan, Rebecca F. McClure, and David Viswanatha Blood 2009 114: 3502-3503. [Full Text] [PDF] This article has been cited by other articles: A. Pardanani, A. Tefferi, M. R. Litzow, C. Zent, W. J. Hogan, R. F. McClure, and D. Viswanatha Chronic myeloid leukemia with p190BCR-ABL: prevalence, morphology, tyrosine kinase inhibitor response, and kinase domain mutation analysis Blood, October 15, 2009; 114(16): 3502 - 3503. [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020